<DOC>
	<DOCNO>NCT02522936</DOCNO>
	<brief_summary>This randomize placebo control trial use Biotene versus treatment woman receive oral oxybutynin overactive bladder . The primary outcome rate discontinuation oxybutynin 6 month .</brief_summary>
	<brief_title>Use Biotene Moisturizing Mouth Spray Xerostomia Associated With Oral Oxybutynin Use</brief_title>
	<detailed_description>Overactive bladder ( OAB ) common condition affect roughly 20 % woman . Anticholinergic medication main treatment modality woman OAB ; however , treatment hamper high rate dry mouth limit tolerability . Discontinuation rate anticholinergic medication dry mouth report high 71 % 6 month . Biotène ( TM ) Moisturizing Mouth Spray use xerostomia due various etiology adult . The purpose study determine rate discontinuation oral oxybutynin therapy overactive bladder woman use Biotène ( TM ) Moisturizing Mouth Spray versus additional treatment . This randomized open label trial . Participants randomize moisturize mouth spray versus additional treatment . Urinary symptom , xerostomia symptom , compliance oral oxybutynin compare group . Our primary outcome rate discontinuation oral oxybutynin 6 month . Assuming baseline discontinuation rate 70 % 6 month , assume 80 % power α = 0.05 two-sided test , require 42 subject group detect difference 30 % cure rate two group . Assuming followup 75 % , 60 subject group recruit . Participants within group compare respect difference baseline demographic , questionnaire score compliance oxybutynin use Chi Square test categorical variable , T test normally distribute continuous variable Mann Whitney U test non-normally distribute ordinal variable .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Muramidase</mesh_term>
	<criteria>Age &gt; 18 Able give inform consent Women diagnose overactive bladder urgency incontinence start oral oxybutynin . Any allergy Biotène® Moisturizing Mouth Spray components Any contraindication oxybutynin , include urinary retention ( PVR &gt; 100ml ) , gastric retention severe decrease gastrointestinal motility condition , uncontrolled narrowangle glaucoma patient risk condition , patient demonstrate hypersensitivity drug substance component product . Using ocular anticholinergic agent , treatment dry mouth oral antimuscarinics precede 3 month . Prior history head/neck surgery radiation ( exclude thyroid surgery ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>